Jury orders Takeda subsidiary to pay Bayer $155 million
06-02-2019
US court rejects motion to dismiss Bayer haemophilia suit
16-03-2018
jarun011 / iStockphoto.com
Bayer HealthCare has filed a lawsuit against Nektar Therapeutics and Baxalta seeking a declaration that a treatment for haemophilia A does not infringe their patent.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bayer, Nektar, Baxalta, patent, haemophilia A, US District Court for the Northern District of California, patent invalidity, BAY 94, US district court
